Cardiac Amyloid (CA), including transthyretin (ATTR) and immunoglobulin light chain (AL) subtypes, is an increasingly recognized etiology of heart failure with preserved ejection fraction (HFpEF) [ 1 ]. Atrial fibrillation (AF) is common in these patients with a prevalence of up to 70 % [ 2 ]. AF poses an increased thrombotic and stroke risk regardless of CHA ₂ DS ₂ -VASc score in patients with CA [ 3 ]. Furthermore, CA predisposes one to an increased risk of intracardiac thrombi with up to ~90 % occur in the left atrial appendage [ 4 ]. Although there is limited data regarding the use of anticoagulation in CA, the AHA/ACC/HFSA Guidelines give a class 2a recommendation for initiating anticoagulation in these patients regardless of CHA ₂ DS ₂ -VASc score [ 5 ]. Percutaneous left atrial appendage occlusion (LAAO) has emerged for patients with a moderate to high stroke risk and an irreversible contraindication to anticoagulation. Although there is limited data, LAAO may be an option for patients with CA. Therefore, we sought to utilize national trends to demonstrate the safety and feasibility of LAAO in patients with CA.